Clinical trial · Interventional
The Safety and Feasibility of Radiofrequency Ablation to Treat Low-risk Thyroid Cancer
Thermo-Ablation With Radiofrequency Medical Technologies to Treat Thyroid Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to test radiofrequency ablation (RFA) in thyroid cancers ≤2 cm in diameter. The main question it aims to answer is: • What is the feasibility of RFA use for low-risk thyroid cancers (≤2 cm)? Participants will undergo a set of pre-procedural scans of the target thyroid nodule and undergo the RFA procedure/intervention. Then, participants will partake in three follow-up appointments at 4 weeks, 6 months, and 12 months post-procedure as per standard of care.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
| Thyroid Nodule | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiofrequency ablation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Intervention
- description
- Participants receive RFA intervention for thyroid nodule.
- interventionNames
- Procedure: Radiofrequency ablation
Primary outcomes (1)
- measure
- Complications
- timeFrame
- Immediately after the procedure, and 4 weeks/6 months/12 months post-procedure.
- description
- Rate of complications, including pain, burns, recurrent laryngeal nerve palsy, hematoma, nodule rupture, and deviation from euthyroidism
Secondary outcomes (7)
- measure
- Effectiveness
- timeFrame
- 4 weeks/6 months/12 months post-procedure.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: 1\. Patients with: * Nodule less than or equal to 2cm in size a. Specifically: Bethesda 5/6 * Their age is ≥18 years and ≤100 years * Able to provide written consent * Able to attend required follow-ups as per the protocol Exclusion Criteria: * Patients \<18 years old * Pregnant women * Any concern for invasive or metastatic thyroid cancer * Previously treated for thyroid cancer
References
Publications (0)
Data not yet available